Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents

01 February 2010 Publication
Authors: Courtenay C. Brinckerhoff

Genetic Engineering & Biotechnology News

Foley Partner Courtenay Brinckerhoff authored an article titled, “Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents” in the Genetic Engineering & Biotechnology News. Brinckerhoff discusses the Federal Circuit’s decision to rehear Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. en banc to resolve an intra-court split over whether 35 USC § 112 imposes a written-description requirement that is separate from the enablement requirement. She reviews how the outcome of the case could have significant impact on biotechnology patents, which are often vulnerable to written-description challenges.

 

Insights

A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ